Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aticaprant Thorough QT Study in Healthy Adults
NCT05387759Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2022
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of aticaprant in major depressive disorder (MDD) and anhedonia ((none)) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Change from Baseline in QTc. Started May 2022; status: completed.
02
Drugs
aticaprant
03
Conditions
major depressive disorder (MDD)anhedonia ((none))
Beyond the preview
Go deeper on NCT05387759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05387759.